Hepatocellular Carcinoma (HCC), Liver Transplantation, Survival Rate, Tyrosine Kinase Inhibitor
Conditions
Keywords
liver transplantation, hepatocellular carcinoma, Tyrosine kinase inhibitor, Survival
Brief summary
Based on the follow-up data of hepatocellular carcinoma (HCC) patients undergoing liver transplantation from the China Liver Transplant Registry (CLTR) and the First Affiliated Hospital of Xi'an Jiaotong University, patients who met the inclusion criteria were assessed for tumor response, post-transplant tumor recurrence, and survival rates. Statistical analysis was performed to evaluate patient prognosis and to identify risk factors affecting outcomes.
Detailed description
A retrospective study was performed on patients who underwent liver transplant for hepatocellular carcinoma (HCC) at the First Affiliated Hospital of Xi'an Jiaotong University between January 2015 and December 2024. Clinical data including demographic characteristics, tumor characteristics, detailed history of pre-transplant antitumor therapy, perioperative laboratory parameters, surgical details, and pathological findings were collected from the hospital's prospective clinical database. Based on follow-up records, patients who met the inclusion criteria were evaluated for tumor response, post-transplant tumor recurrence and overall survival. Statistical analyses were conducted to assess postoperative prognosis and to identify risk factors associated with clinical outcomes.
Interventions
OTHERMedication history
The study was retrospective and did not involve the application of interventions.
Sponsors
Hu Liangshuo
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years and ≤ 75 years; 2. HCC diagnosis confirmed through imaging and elevated serum alpha-fetoprotein (AFP); 3. Underwent liver transplantation for hepatocellular carcinoma. 4. Underwent primary (first-time) liver transplantation. 5. Availability of complete clinical and follow-up data for analysis.
Exclusion criteria
1. age \<18 years or \>75 years; 2. living-donor liver transplantation or re-transplantation; 3. concurrent active malignancy other than HCC; 4. incomplete key baseline data or follow-up information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-operative survival time | Time from the end of liver transplantation to the patient's death, or the end of follow-up by December 31, 2024. whichever came first, assessed up to 60 months. | Postoperative survival time for patients receiving liver transplantation |
| Recurrence of the primary disease after surgery | The time period between liver transplantation and the initial examination revealing a recurrence of primary disease, or until the end of follow-up on December 31, 2024.whichever came first, assessed up to 60 months. | Recurrence of primary disease in patients who underwent liver transplantation after surgery |
| Transplanted liver status | Time from the end of liver transplantation to the patient's death, or the end of follow-up by December 31, 2024. whichever came first, assessed up to 60 months.The functional status of the transplanted liver was recorded during this period. | Postoperative Liver Function in Patients Undergoing Liver Transplantation. To monitor post-transplant liver status regularly through assessment of key liver function biochemical indices (including AST, ALT, bilirubin, etc.) and liver imaging examinations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with intraoperative indicators | Intraoperative | Record important intraoperative indicators during the transplantation procedure, including operative time, warm ischemia time, cold ischemia time, anhepatic phase duration, intraoperative blood loss, volume of red blood cells transfused, and total intravenous fluid volume. |
| Post-operative complications in patients who underwent liver transplantation | Time from the end of liver transplantation to the patient's death, or the end of follow-up by December 31, 2024. whichever came first, assessed up to 60 months.During this period, all postoperative complications of the patient will be recorded. | Specific details of all post-operative complications in patients who underwent liver transplantation |
Countries
China
Outcome results
None listed